LAURUSLABS · Healthcare
Laurus Labs Ltd. reported revenue of ₹1,224 cr for July to September 2024, 0.0% on the year and +2.4% on the quarter.
Operating profit (EBITDA) was ₹178 cr, a margin of 14.5%, −82 bps on the year and +23 bps on the quarter. Over the last 6 quarters the margin has ranged from 14.1% to 16.7%, averaging 15.0%. Operating costs grew +1.0%, faster than revenue at 0.0%, so operating profit grew less than sales.
Net profit was ₹20.0 cr, −45.9% on the year and +53.8% on the quarter, with earnings per share of ₹0.37. Profit before other income, one-offs and tax fell 65.4%, so 19 points of the headline growth came from outside the core business. The tax rate was 22% against an average of 30% over the previous 5 quarters, which lifted profit this quarter.
On earnings per share of ₹2.43 over the last four quarters, the stock at ₹2,058.50 trades at 847.1 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,224 cr | ₹1,195 cr | ₹1,440 cr | ₹1,195 cr | ₹1,224 cr | ₹1,415 cr | ₹1,720 cr | ₹1,570 cr | ₹1,653 cr | ₹1,778 cr | ₹1,812 cr | ₹2,026 cr |
| YoY | — | — | — | +1% | 0% | +18% | +19% | +31% | +35% | +26% | +5% | +29% |
| EBITDA margin | 15.4% | 15.1% | 16.7% | 14.3% | 14.5% | 20.1% | 24.5% | 24.3% | 24.4% | 27.0% | 28.3% | 31.5% |
| Other income, % of PBT | 4% | 6% | 18% | 17% | 22% | 7% | 19% | 4% | 10% | 2% | 3% | 2% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 27% | 27% | 30% | 34% | 22% | 31% | 25% | 28% | 28% | 22% | 22% | 25% |
| Net profit | ₹37.0 cr | ₹23.0 cr | ₹75.0 cr | ₹13.0 cr | ₹20.0 cr | ₹93.0 cr | ₹233 cr | ₹162 cr | ₹194 cr | ₹252 cr | ₹282 cr | ₹362 cr |
| YoY | — | — | — | −52% | −46% | +304% | +211% | +1,146% | +870% | +171% | +21% | +123% |
| Core profit YoY | — | — | — | −59% | −65% | +270% | +188% | +1,327% | +1,250% | +163% | +38% | +121% |
| EPS | ₹0.69 | ₹0.43 | ₹1.40 | ₹0.23 | ₹0.37 | ₹1.71 | ₹4.33 | ₹3.02 | ₹3.61 | ₹4.66 | ₹5.17 | ₹6.80 |
| Flags | · | · | · | ✓ | ✓ | 1 | 1 | ✓ | ✓ | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Laurus Labs Ltd. reported revenue of ₹1,224 cr (0.0% on the year) and net profit of ₹20.0 cr (−45.9% on the year) for July to September 2024.
Profit before other income, exceptional items and tax moved −65.4% on the year, against −45.9% for reported profit.
None of the 7 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.